Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of systemic therapy in metastatic phyllodes tumor of the breast.
Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Parkes A, et al. Breast Cancer Res Treat. 2021 Apr;186(3):871-882. doi: 10.1007/s10549-021-06116-8. Epub 2021 Feb 11. Breast Cancer Res Treat. 2021. PMID: 33575859
Dedifferentiated Liposarcoma: Systemic Therapy Options.
Gahvari Z, Parkes A. Gahvari Z, et al. Among authors: parkes a. Curr Treat Options Oncol. 2020 Feb 5;21(2):15. doi: 10.1007/s11864-020-0705-7. Curr Treat Options Oncol. 2020. PMID: 32026050 Review.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Kamaraju S, Fowler AM, Tarima S, Chaudhary LN, Burkard ME, Giever T, Cheng YC, Parkes A, Lange CA, Pipp-Dahm M, Hegeman R, Siddiqui N, Stella A, Rajguru S, Twaroski K, Zurbriggen L, Jorns JM, Rui H, Keigley QJ, Perlman SB, Salem K, Bradshaw TJ, Sahmoud T, Wisinski K. Kamaraju S, et al. Among authors: parkes a. Clin Breast Cancer. 2024 Dec 10:S1526-8209(24)00333-1. doi: 10.1016/j.clbc.2024.11.019. Online ahead of print. Clin Breast Cancer. 2024. PMID: 39824712
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy.
Hirbe AC, Eulo V, Moon CI, Luo J, Myles S, Seetharam M, Toeniskoetter J, Kershner T, Haarberg S, Agulnik M, Monga V, Milhem M, Parkes A, Robinson S, Okuno S, Attia S, Van Tine BA. Hirbe AC, et al. Among authors: parkes a. Eur J Cancer. 2020 Sep;137:1-9. doi: 10.1016/j.ejca.2020.06.016. Epub 2020 Jul 23. Eur J Cancer. 2020. PMID: 32712457 Clinical Trial.
Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA. von Mehren M, et al. Among authors: parkes am. J Natl Compr Canc Netw. 2022 Jul;20(7):815-833. doi: 10.6004/jnccn.2022.0035. J Natl Compr Canc Netw. 2022. PMID: 35830886 Free PMC article.
384 results